Abstract
The antimicrobial crisis is a major problem as resistant bacteria infections have increased and the availability of effective antibiotics have been reduced. Gram-negative bacilli are responsible for frequent and potentially severe bloodstream infections, among which up to 47% can be produced by Enterobacteria (EB).The optimal duration of antibiotic treatment in this clinical setting is unknown, as no clinical trials (CT) have been designed to answer this question. Moreover, the role of biomarkers such as procalcitonine (PCT) in this setting has not been established.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
